Encephalopathy cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 1: | Line 1: | ||
{{ | {{Encephalopathy}} | ||
{{CMG}} ; {{AE}} {{ADI}} | {{CMG}} ; {{AE}} {{ADI}} | ||
Revision as of 05:21, 23 July 2012
|
Encephalopathy |
|
Diagnosis |
|---|
|
Treatment |
|
Encephalopathy cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Encephalopathy cost-effectiveness of therapy |
|
Risk calculators and risk factors for Encephalopathy cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2]
Overview
Financial Costs
- Cost effectiveness of various therapies depends on the condition.
- Hypothermia - Neonatal Encephalopathy - The incremental cost per disability-free life year gained was US$28,124 (£19,931 ; €26,920) as per the data of 2006 Organisation for Economic Co-operation and Development (OECD). [1]
References
- ↑ Regier DA, Petrou S, Henderson J; et al. (2010). "Cost-effectiveness of therapeutic hypothermia to treat neonatal encephalopathy". Value Health. 13 (6): 695–702. doi:10.1111/j.1524-4733.2010.00731.x. PMID 20561343.